

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



丽珠医药
LIVZON

麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

ANNOUNCEMENT ON PROGRESS OF REPURCHASE OF H SHARES

References are made to the circular (the “**Circular**”) dated 7 December 2020 and the announcements dated 1 December 2020, 4 January 2021, 5 January 2021, 6 January 2021, 7 January 2021, 8 January 2021, 11 January 2021, 27 January 2021, 28 January 2021, 29 January 2021, 1 February 2021, 2 February 2021, 3 February 2021, 4 February 2021, 5 February 2021 and 1 March 2021 of 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* (the “**Company**”, together with its subsidiaries, the “**Group**”) in relation to the grant of general mandate to the Board to repurchase H shares of the Company (the “**H Share Repurchase Mandate**”), the monthly returns and the next day disclosure returns. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

As at 31 March 2021, the Company made a total repurchase of 6,628,600 H Shares of the Company, accounting for 0.71% of the total issued share capital (939,095,504 shares) and 2.07% of the total number of issued H Shares (319,864,217 shares) of the Company on 31 March 2021. The highest purchase price was HK\$31.90 per share and the lowest purchase price was HK\$28.35 per share. The total amount of funds used was HK\$199,632,345.00 (excluding transaction costs). The share repurchase mentioned above complies with the H Share Repurchase Mandate.

Subsequently, the Company will implement the H Share Repurchase Mandate and perform its disclosure obligations in a timely manner in strict accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and other relevant provisions. Investors are kindly reminded to pay attention to possible investment risks.

By order of the Board
麗珠醫藥集團股份有限公司
Livzon Pharmaceutical Group Inc. *
Yang Liang
Company Secretary

Zhuhai, China
1 April 2021

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Qiu Qingfeng and Mr. Yu Xiong; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Zheng Zhihua, Mr. Xie Yun, Mr. Tian Qiusheng and Mr. Wong Kam Wa.

** For identification purpose only*